UBS Initiates Gilead Sciences(GILD.US) With Hold Rating, Announces Target Price $96

瑞士銀行首次給予吉利德科學(GILD.US)持有評級，目標價96美元

富途資訊 · 2024/11/22 00:31 · 評級/大行評級

UBS analyst Eliana Merle initiates coverage on $Gilead Sciences (GILD.US)$ with a hold rating, and sets the target price at $96.

According to TipRanks data, the analyst has a success rate of 34.8% and a total average return of -7.1% over the past year.

AnalystRecentRatingAutoNews_206491_20241121_4736cfddb5865d0cbb199a733512b94dc3309483_1732206607063198_nn_en

Furthermore, according to the comprehensive report, the opinions of $Gilead Sciences (GILD.US)$'s main analysts recently are as follows:

The firm noted an increase in their HIV PrEP and Livdelzi estimates for Gilead, and anticipates meaningful growth in Gilead's HIV base business due to the expansion of the PrEP market with the introduction of lenacapravir. Despite a 30% increase in share value over the past six months, the growth of the PrEP market remains uncertain, leading to the current valuation of the shares being deemed appropriate.
Following the Q3 reports, updated models in the biotechnology group suggest growth for Gilead's base HIV business, with the potential launch of lenacapavir anticipated around late 2025.

Note:

TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.

Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.

TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.

瑞士銀行分析師Eliana Merle首次給予$吉利德科學 (GILD.US)$持有評級，目標價96美元。

根據TipRanks數據顯示，該分析師近一年總勝率為34.8%，總平均回報率為-7.1%。

AnalystRecentRatingAutoNews_206491_20241121_4736cfddb5865d0cbb199a733512b94dc3309483_1732206607063198_nn_tc

此外，綜合報道，$吉利德科學 (GILD.US)$近期主要分析師觀點如下：

該公司注意到對吉利德的HIV預防用藥(PrEP)和Livdelzi的估計有所增加，並預計由於lenacapravir的推出，吉利德的HIV基礎業務將實現有意義的增長。儘管過去六個月股價上漲了30%，但PrEP市場的增長仍然不確定，因此目前對其股價的估值被認爲合理。
在第三季度報告後，生物技術組的更新模型顯示吉利德的HIV基礎業務將增長，預計lenacapavir的潛在推出將在2025年末左右。

提示:

TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。

TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。

分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。

總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。

譯文內容由第三人軟體翻譯。

以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。

UBS Initiates Gilead Sciences(GILD.US) With Hold Rating, Announces Target Price $96

UBS Initiates Gilead Sciences(GILD.US) With Hold Rating, Announces Target Price $96

風險及免責聲明

聲明